Home > Neurology > EAN 2020 > Multiple Sclerosis > High NEDA rates after 2 years of ocrelizumab

High NEDA rates after 2 years of ocrelizumab

In the CASTING open-label single-arm prospective trial, the proportion of patients with no evidence of disease activity (NEDA) at Year 2 was high: 74.8%–80.4% of patients were free from clinical disease activity, while 91.5% of patients were free from MRI disease activity [1]. NEDA was maintained from Year 1 over Year 2. No new safety signals were observed.

The CASTING results were presented as a late-breaking abstract by Prof. Patrick Vermersch (CHU Lille, France). CASTING is a phase 3b study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) patients with suboptimal response to 1 or 2 prior disease-modifying treatments (DMTs). Prof. Vermersch reported the study's primary efficacy endpoint, 2-year NEDA rates, including:
- no protocol-defined relapses;
- no 24-week confirmed disability progression;
- no T1-weighted gadolinium-enhancing lesions after Week 8 re-baselining;
- no new/enlar...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on